RET and non-small cell lung carcinoma: In NSCLC, more than ten RET fusion partners have been described,[3,6] among which KIF5B-RET occurs the most frequently with the prevalence ranging from 40% to 72%,[1,7] followed by CCDC6 (10-25%).